Mobius 2000 Liter Single-Use Bioreactor

July 26, 2015

Full Name: Mobius® 2000 Liter Single-Use Bioreactor

 EMD Millipore

Status: Highly developed, ready for commercial-scale bioprocessing

Debut: June, 2015

Field Position: Leads biopharmaceutical process team

Skill Set: Ease of use, flexible configuration

Performance Stats:
• Industry’s first bottom-loading drawer enables easiest Flexware assembly installation on the market
• 5:1 turndown ratio provides the most flexible seeding and growth strategy
• Patent-pending baffle design gives the mixing performance of a stainless steel bioreactor with no cleaning required

Regulatory Profile: Meets or exceeds cGMP compliance expectations

Coach’s Notes: “Successful development of upstream processes demands flexibility, scalability and ease of use,” said Udit Batra, president and CEO, EMD Millipore. “Our ground-breaking Mobius 2000 liter single-use bioreactor delivers these essential benefits, including superior mixing, 5:1 turndown ratio, and critical ease of use. Our complete upstream and downstream portfolio supports GMP production and allows our customers to move molecules faster and more reliably into the clinic and to market.”

Scout’s Notes: "The 2000 liter bioreactor joins the Mobius® stirred tank bioreactor portfolio (from 3 to 2000 liters) that provides the ultimate in flexibility, scalability, and convenience. With configurable software, hardware, and single-use Flexware®assemblies for suspension and adherent cell culture applications, the new 2000 liter single-use bioreactor incorporates industry-leading design features that enable users to easily optimize their upstream process."

Team Resources: Headquartered in Billerica, Massachusetts, EMD Millipore is the U.S. Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, EMD Millipore offers a broad range of innovative, performance products, services and business relationships that enable its customers' success in research, development and production of biotech and pharmaceutical drug therapies.